Details of the Drug Reposition

General Information of This Drug (ID: DM9MF08)

• Drug Name: OBP-301 (DM9MF08)

Information on Drug Reposition of This Drug

3 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Liver cancer	DISDE4BI	2C12	Phase 1/2	[1]
Breast cancer	DIS7DPX1	2C60-2C65	Phase 1/2	[1]
Head and neck cancer	DISBPSQZ	2D42	Phase 1/2	[1]

References

• [1] ClinicalTrials.gov (NCT02293850) Phase I/II Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma. U.S. National Institutes of Health.